ArticleESMO gastrointestinal oncology2025
Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment.
F Rossari et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.